Indivior PLC Ordinary Shares (INDV)vsTeva Pharma Industries Ltd ADR (TEVA)
INDV
Indivior PLC Ordinary Shares
$30.26
+5.11%
HEALTHCARE · Cap: $3.66B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1293% more annual revenue ($17.26B vs $1.24B). INDV leads profitability with a 17.0% profit margin vs 8.2%. INDV trades at a lower P/E of 17.9x. TEVA earns a higher WallStSmart Score of 73/100 (B).
INDV
Buy62
out of 100
Grade: C+
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+55.6%
Fair Value
$76.75
Current Price
$30.26
$46.49 discount
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 37.1%
Attractively priced relative to earnings
19.7% revenue growth
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
3.8% earnings growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : INDV
The strongest argument for INDV centers on Operating Margin, P/E Ratio, Revenue Growth. Profitability is solid with margins at 17.0% and operating margin at 37.1%. Revenue growth of 19.7% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : INDV
The primary concerns for INDV are EPS Growth, Free Cash Flow.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
INDV profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.19 — expect wider price swings.
INDV is growing revenue faster at 19.7% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 62/100) and 11.4% revenue growth. INDV offers better value entry with a 55.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?